Using Tumor Gene Therapy to Overcome Barriers to Immunotherapies

Howard Davis, CEO of Akamis Bio, discusses the challenges immunotherapies have faced in addressing solid tumors, the company’s tumor gene therapy platform, and how it turns tumors against themselves to stimulate an immune response.